| Systematic (IUPAC) name | |
|---|---|
| 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[N-(2-chlorobenzyl)-N,N-diethylethanaminium] | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a699058 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | Low |
| Identifiers | |
| CAS number | 7648-98-8 |
| ATC code | N07AA30 |
| PubChem | CID 8288 |
| DrugBank | DB01122 |
| ChemSpider | 7987 |
| UNII | L16PUN799N |
| KEGG | D01001 |
| ChEBI | CHEBI:2628 |
| ChEMBL | CHEMBL1652 |
| Chemical data | |
| Formula | C28H42Cl2N4O2+2 |
| Mol. mass | 537.564 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Ambenonium (as ambenonium dichloride, trade name Mytelase) is a cholinesterase inhibitor[1] used in the management of myasthenia gravis.
It is classified as reversible.[2]
Ambenonium exerts its actions against Myasthenia Gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia Gravis occurs when the body produces antibodies against acetylcholine receptors, and thus inhibits signal transmission across the myoneural junction. Ambenonium reversibly binds acetylcholinesterase, inactivates it and therefore increases levels of acetylcholine. This, in turn, facilitates transmission of impulses across the myoneural junction and effectively treats the disease
Ambenonium is used to treat muscle weakness due to muscle disease (myasthenia gravis).
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)